Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).
ANNA members are encouraged to invite Congressional delegations, Centers for Medicare and Medicaid Services (CMS) staff, ESRD regional office staff, and local and regulatory agency staff to visit a local dialysis facility, transplant center, or KEEP program during Kidney Disease Awareness and Education Week. The objective of these visits is to educate policymakers about kidney disease, treatment options, and the legislative issues facing the renal community.
In this regard, Kibow is also a proud participant and contributor to R&D of the maintenance of a healthy kidney function. The company's flagship product, Kibow(R) Biotics, utilizes a patented and proprietary bowel-based enteric technology concept for use in worldwide clinical applications towards maintaining a healthy kidney function.
Kibow has recently completed a pilot-scale study with a limited number of patients in USA, Canada, Argentina and Nigeria. The positive outcome from this study will be published in the peer-reviewed "Advances in Therapy" publication. This report, titled "Pilot Study of Probiotic Dietary Supplementation for Promoting Healthy Kidney Function in Patients with Chronic Kidney Disease," can be accessed freely online in the coming month at either our website (http://www.kibow.com) or the journal's website (http://www.advancesintherapy.com).
Dr. Natarajan Ranganathan, Interim CEO and VP Research and Development, stated, "By offering an affordable, readily available and easy-to-administer dietary supplement product in the USA, Kibow aims to make Kibow(R) Biotics accessible to all those who suffer from kidney problems in other countries worldwide according to individual countries' governmental regulatory/registration authorities."
Novel multi-biomarker approach enhances chronic kidney disease risk assessment